{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:12:16Z","timestamp":1776867136231,"version":"3.51.2"},"reference-count":23,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2016,2,2]],"date-time":"2016-02-02T00:00:00Z","timestamp":1454371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hemodialysis International"],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We retrospectively identified patients with end\u2010stage renal disease undergoing hemodialysis treated with the mammalian target of rapamycin inhibitors as a second\u2010 and\/or third\u2010line targeted therapy after treatment failure with the tyrosine kinase inhibitors for metastatic renal cell carcinoma. Patient medical records were reviewed to evaluate the response to therapies and treatment\u2010related toxicities. Four patients were identified. All patients had undergone nephrectomy, and one had received immunotherapy before targeted therapy. Two patients had clear cell histology, and the other two had papillary histology. All patients were classified into the intermediate risk group according to the Memorial Sloan\u2010Kettering Cancer Center risk model. All patients were treated with everolimus as a second\u2010 or third\u2010line therapy, and two patients were treated with temsirolimus as a second\u2010 or third\u2010line therapy after treatment failure with sorafenib or sunitinib. The median duration of everolimus therapy was 6.7 months, whereas that of temsirolimus was 9.5 months. All patients had stable disease as the best response during each period of therapy. There were no severe adverse events. The use of mammalian target of rapamycin inhibitors in patients who previously failed to respond to tyrosine kinase inhibitors appears to be feasible in patients with end\u2010stage renal disease requiring hemodialysis.<\/jats:p>","DOI":"10.1111\/hdi.12390","type":"journal-article","created":{"date-parts":[[2016,2,2]],"date-time":"2016-02-02T07:02:00Z","timestamp":1454396520000},"source":"Crossref","is-referenced-by-count":10,"title":["Use of mammalian target of rapamycin inhibitors after failure of tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma undergoing hemodialysis: A single\u2010center experience with four cases"],"prefix":"10.1111","volume":"20","author":[{"given":"Kenji","family":"Omae","sequence":"first","affiliation":[{"name":"Department of Urology Tokyo Women's Medical University 8\u20101 Kawadacho Shinjuku Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsunenori","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Urology Tokyo Women's Medical University 8\u20101 Kawadacho Shinjuku Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Takagi","sequence":"additional","affiliation":[{"name":"Department of Urology Tokyo Women's Medical University 8\u20101 Kawadacho Shinjuku Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junpei","family":"Iizuka","sequence":"additional","affiliation":[{"name":"Department of Urology Tokyo Women's Medical University 8\u20101 Kawadacho Shinjuku Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohito","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Urology Tokyo Women's Medical University 8\u20101 Kawadacho Shinjuku Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunobu","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Urology Tokyo Women's Medical University 8\u20101 Kawadacho Shinjuku Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunari","family":"Tanabe","sequence":"additional","affiliation":[{"name":"Department of Urology Tokyo Women's Medical University 8\u20101 Kawadacho Shinjuku Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,2,2]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(12)80058-8"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2002.00374.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1995.286"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1774-9987.2004.00192.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.08817.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09990.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.10946.x"},{"key":"e_1_2_6_9_1","volume-title":"World Health Organization Classification of Tumours","author":"Eble JN","year":"2004"},{"key":"e_1_2_6_10_1","unstructured":"National Cancer Institute. Cancer Therapy Evaluation Program. Available from:http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_40(accessed October 18 2015)."},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.02.035"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu259"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1995.132"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000019641.41496.1E"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00050.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147\u2010015\u20100871\u2010y"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.3342"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.1293"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2129-6"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.12471"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds477"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.3144"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-012-0492-7"}],"container-title":["Hemodialysis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhdi.12390","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hdi.12390","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T07:16:46Z","timestamp":1695539806000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hdi.12390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,2]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["10.1111\/hdi.12390"],"URL":"https:\/\/doi.org\/10.1111\/hdi.12390","archive":["Portico"],"relation":{},"ISSN":["1492-7535","1542-4758"],"issn-type":[{"value":"1492-7535","type":"print"},{"value":"1542-4758","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,2]]}}}